NCT05293470View on ClinicalTrials.gov

A Post Marketing Surveillance on Piqray in Korea

RecruitingOBSERVATIONAL
Enrollment

900

Participants

Timeline

Start Date

June 29, 2022

Primary Completion Date

May 12, 2027

Study Completion Date

May 12, 2027

Conditions
Breast Cancer
Interventions
OTHER

Piqray

There is no treatment allocation. Patients administered Piqray by prescription will be enrolled.

Trial Locations (17)

10475

RECRUITING

Novartis Investigative Site, Deogyang Gu Goyang Si

11765

RECRUITING

Novartis Investigative Site, Gyeonggi-do

16499

RECRUITING

Novartis Investigative Site, Suwon

31116

RECRUITING

Novartis Investigative Site, Cheonan Si

42602

RECRUITING

Novartis Investigative Site, Daegu

48108

RECRUITING

Novartis Investigative Site, Busan

519763

RECRUITING

Novartis Investigative Site, Jeollanam

602-030

RECRUITING

Novartis Investigative Site, Busan

705 718

RECRUITING

Novartis Investigative Site, Daegu

302-241

RECRUITING

Novartis Investigative Site, Daejeon

02841

RECRUITING

Novartis Investigative Site, Seoul

03722

RECRUITING

Novartis Investigative Site, Seoul

04763

RECRUITING

Novartis Investigative Site, Seoul

05505

RECRUITING

Novartis Investigative Site, Seoul

06273

RECRUITING

Novartis Investigative Site, Seoul

06351

COMPLETED

Novartis Investigative Site, Seoul

158-710

RECRUITING

Novartis Investigative Site, Seoul

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY